Sugi Predict

Sugi Predict / Compounds / SCHEMBL3512013

SCHEMBL3512013

SCHEMBL3512013

N#Cc1cc(Cc2ccccc2)ccc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IDH1 O75874 1/20 0.43
▸ CALM1 P0DP23 1/20 0.43
▸ CNR2 P34972 1/20 0.40
▸ MAOB P27338 3/20 0.40
▸ MAOA P21397 2/20 0.40
▸ GPR52 Q9Y2T5 1/20 0.40
▸ TRPV4 Q9HBA0 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ LTA4H P09960 1/20 0.38
▸ FNTA P49354 1/20 0.38
▸ FNTB P49356 1/20 0.38
▸ PGGT1B P53609 1/20 0.38
▸ GRM4 Q14833 1/20 0.38
▸ HNF4A P41235 1/20 0.38
▸ ACLY P53396 1/20 0.37
▸ FLT3 P36888 1/20 0.37
▸ ABCG2 Q9UNQ0 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30037290 1.00 IDH1 (0.43) IDH1CALM1CNR2MAOBMAOA
SCHEMBL24872544 0.91 TRPV4 (0.45) CNR2MAOBMAOAGPR52TRPV4
SCHEMBL3512037 0.86 TAAR1 (0.44) MAOBGPR52TRPV4KDM4EHPGD
SCHEMBL3305103 0.86 TRPV4 (0.52) IDH1CALM1MAOBMAOAGPR52
SCHEMBL30128532 0.82 TRPV4 (0.39) MAOBMAOAGPR52TRPV4SNCA
SCHEMBL3512960 0.82 TRPV4 (0.39) MAOBMAOAGPR52TRPV4SNCA
SCHEMBL3512964 0.81 NR1D1 (0.48) GPR52KDM4EHPGDTSHRHSD17B10
SCHEMBL30862000 0.81 NR1D1 (0.48) GPR52KDM4EHPGDTSHRHSD17B10
SCHEMBL28704253 0.80 MAOB (0.48) MAOBMAOAKDM4ETSHRLTA4H
SCHEMBL28707856 0.80 TAAR1 (0.46) MAOBLTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435061-B2 Compounds and compositions for use in treating skin disorders KAMARI PHARMA LTD. (IL) 2025-10-07 — — US disclosed
EP-4574822-A2 COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS Kamari Pharma Ltd. (IL) 2025-06-25 — — EP disclosed
CN-118702672-A Compounds and compositions for treating skin disorders 卡玛瑞制药有限公司 2024-09-27 — — CN disclosed
CN-115335050-B Compounds and compositions for treating skin disorders 卡玛瑞制药有限公司 2024-05-17 — — CN disclosed
US-20240124413-A1 COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS KAMARI PHARMA LTD. (IL) 2024-04-18 — — US disclosed
US-11807621-B2 Compounds and compositions for use in treating skin disorders KAMARI PHARMA LTD. (IL) 2023-11-07 — — US disclosed
US-11807621-B2 Compounds and compositions for use in treating skin disorders KAMARI PHARMA LTD. (IL) 2023-11-07 — — US disclosed
US-11807621-B2 Compounds and compositions for use in treating skin disorders KAMARI PHARMA LTD. (IL) 2023-11-07 — — US disclosed
EP-4096661-A1 COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS Kamari Pharma Ltd. (IL) 2022-12-07 — — EP disclosed
CN-115335050-A Compounds and compositions for treating skin conditions 卡玛瑞制药有限公司 2022-11-11 — — CN disclosed
US-20130018036-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-01-17 — — US disclosed
US-8299057-B2 Substituted indazole derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-10-30 — — US disclosed
US-20100292207-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-11-18 — — US disclosed
CN-101754956-A Substituted indazole derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES SRL 2010-06-23 — — CN disclosed
EP-2176231-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2010-04-21 — — EP disclosed
WO-2009013126-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-01-29 — — WO disclosed
EP-1082121-A4 HIV INTEGRASE INHIBITORS MERCK & CO INC (US) 2003-02-05 — — EP disclosed
US-6380249-B1 HIV integrase inhibitors MERCK & CO., INC. 2002-04-30 — — US disclosed
EP-1082121-A1 HIV INTEGRASE INHIBITORS Merck & Co., Inc. (US) 2001-03-14 — — EP disclosed
WO-1999062520-A1 HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 1999-12-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12435061-B2 Compounds and compositions for use in treating skin disorders RDX, HAX1, F12 IDH1 2780/4885CALM1 4206/4885CNR2 2393/4885
US-20100292207-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS MAP3K19, MAP3K3, MAP3K5 IDH1 484/4885CALM1 1496/4885CNR2 4227/4885
US-20130018036-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS MAP3K19, MAP3K3, MAP3K5 IDH1 484/4885CALM1 1496/4885CNR2 4227/4885
US-20240124413-A1 COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS RDX, HAX1, F12 IDH1 2780/4885CALM1 4206/4885CNR2 2393/4885
US-11807621-B2 Compounds and compositions for use in treating skin disorders RDX, HAX1, F12 IDH1 2780/4885CALM1 4206/4885CNR2 2393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.